The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. ARCA biopharma's quick ratio for the quarter that ended in Jun. 2024 was 26.61.
ARCA biopharma has a quick ratio of 26.61. It generally indicates good short-term financial strength.
The historical rank and industry rank for ARCA biopharma's Quick Ratio or its related term are showing as below:
ABIO'
s Quick Ratio Range Over the Past 10 Years
Min: 5.94 Med: 14.92 Max: 59.01
Current: 26.61
During the past 13 years, ARCA biopharma's highest Quick Ratio was 59.01. The lowest was 5.94. And the median was 14.92.
ABIO's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.38
vs ABIO: 26.61
ARCA biopharma Quick Ratio Historical Data
The historical data trend for ARCA biopharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ARCA biopharma's Quick Ratio
For the Biotechnology subindustry, ARCA biopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARCA biopharma's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARCA biopharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where ARCA biopharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
ARCA biopharma's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma (NAS:ABIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
ARCA biopharma Quick Ratio Related Terms
Thank you for viewing the detailed overview of ARCA biopharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABIO has been successfully added to your 